What Is Semax?

Published August 2026 · Patriot Labs Research Team · ~14 min read

ACTH, minus the hormone

Adrenocorticotropic hormone is a chain of thirty-nine amino acids that the pituitary releases as part of the body’s stress response. Its most famous job is at the adrenal glands, where it drives the production of cortisol and other steroids — the “corticotropic” action its name records. But researchers noticed decades ago that ACTH does something else as well, something happening in the brain rather than the adrenals: fragments of the molecule appeared to influence learning, memory, and attention in animal models, and to act on nerve cells directly. Those two activities — the steroid-driving one and the brain-facing one — turned out to live in different parts of the hormone.

Semax is the brain-facing part, isolated and made durable. It is a synthetic peptide corresponding to a short neurotrophic stretch of ACTH, extended with a small stabilizing tail, and it was designed so that it keeps the neurotropic character of that region while carrying none of the adrenal, steroidogenic activity of the full hormone. That separation is the whole idea of the molecule, and it is worth stating plainly because it is the thing most easily lost in casual descriptions: Semax is not “a form of ACTH” that a laboratory can use as a stress hormone. It is a fragment analogue that keeps one activity and discards the other. To place it in the wider family, the site’s overview of what peptides are is the natural starting point, and its survey of cognition-related research peptides sets Semax beside the other compounds it is most often studied alongside.

The chemistry: seven residues and a proline tail

Semax is a heptapeptide — seven amino acids — and in one-letter code the sequence is MEHFPGP: methionine, glutamate, histidine, phenylalanine, proline, glycine, proline.¹ Written out in full it is Met-Glu-His-Phe-Pro-Gly-Pro, or in the formal chemical name L-methionyl-L-α-glutamyl-L-histidyl-L-phenylalanyl-L-prolylglycyl-L-proline. The first four residues — Met-Glu-His-Phe — are lifted directly from ACTH; the last three — Pro-Gly-Pro — are the added part, and understanding why they were added is the first thing worth knowing about the molecule.

The peptide carries the molecular formula C₃₇H₅₁N₉O₁₀S, an average molecular weight of roughly 813.9 g/mol, and the CAS registry number 80714-61-0.¹ The lone sulphur atom in that formula belongs to the N-terminal methionine, a residue that will matter again when the handling section turns to stability. The Pro-Gly-Pro tail is the design’s central trick. Short natural peptides are fragile: the body is full of peptidase enzymes that trim amino acids off the ends of a chain, and an unprotected fragment of ACTH would be broken down almost as soon as it appeared. Proline is awkwardly shaped for those enzymes to process, and a Pro-Gly-Pro cap at the C-terminus makes the chain markedly more resistant to that trimming. The result is a peptide short enough to synthesize easily and stable enough to survive being studied — the same stabilization strategy that its sibling Selank uses, and a large part of why both molecules exist at all.

The rest of the sequence is unexotic in the useful sense: a short chain with a single basic histidine, an acidic glutamate, and no unusual modifications beyond the proline tail. That is exactly why it can be made reliably by standard solid-phase peptide synthesis, and why its identity and purity are straightforward to verify with routine analytical tools. Short, defined, and synthesizable is the combination that makes a peptide practical for laboratory work.

Semax, N-acetyl Semax, and the ACTH labels

Search for this molecule and several names come back, some of them used loosely. The peptide is labelled ACTH(4–7)-PGP in the technical literature — a compact way of writing “the fourth-through-seventh residues of ACTH, plus a Pro-Gly-Pro tail.” It is also frequently described as an analogue of ACTH(4–10), because the design grew out of research on that slightly longer neurotropic fragment of the hormone. Both descriptions point at the same molecule; the precise, unambiguous statement is the sequence itself, MEHFPGP, and a research audience is well served by keeping the sequence in mind rather than the shorthand.

A second source of confusion is the family of acetylated variants. N-acetyl Semax adds an acetyl group to the front of the chain, and N-acetyl Semax amidate (sometimes written NASA) adds that acetyl group and also converts the C-terminus to an amide. Both changes are made for the same reason the Pro-Gly-Pro tail exists — to slow enzymatic breakdown further — and they are genuinely different molecules, with different masses and different catalogue entries. The distinction matters for anyone comparing certificates of analysis: “Semax” and “N-acetyl Semax” are not interchangeable labels, and a vial should be characterized as whichever one it actually is. It is the same lesson the site’s guide to reading a certificate of analysis returns to repeatedly: the name on the label is a claim, and the analytics are what confirm it.

A Soviet-era idea about regulatory peptides

The scientific groundwork was laid in the Soviet Union, in a research tradition that took “regulatory peptides” — short peptides that modulate the nervous system — far more seriously than most Western programmes did at the time. The work is associated with the physiologist Ivan Ashmarin and colleagues, and the molecule itself was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow. Semax first appeared in the scientific literature in 1991, in work by Potaman, Alfeeva, Kamensky and co-workers examining how the ACTH(4–10) fragment is degraded and how its stability could be improved — the practical problem the Pro-Gly-Pro tail was designed to solve.²

The premise of the program was the separation described above, now stated as a design thesis: the neurotropic activity of ACTH was already known, but the hormone’s steroidogenic action made the intact molecule useless as a tool for studying the brain in isolation. If a fragment could reproduce only the neurotropic character, and if a proline tail could keep that fragment intact long enough to act, the result would be a stable, brain-selective research peptide. That is what Semax became. In the decades since, it has appeared in well over a hundred published papers — an unusually deep literature for a peptide of its size — and it entered Russian clinical medicine, a regulatory path with no parallel elsewhere that the status section returns to. The broader story of how these Russian regulatory peptides came to exist is one reason the compound is studied so often alongside Epithalon and its stablemate Selank, both products of the same national research culture.

The pathways the studies point to

What Semax is studied to do, and how, comes mainly from cell and animal work, and the most consistent finding concerns the neurotrophins — the growth-factor proteins that support the survival and plasticity of nerve cells. In rodent models Semax has been reported to rapidly raise the expression and levels of brain-derived neurotrophic factor (BDNF) and its signalling receptor TrkB in the hippocampus, and related work describes effects on nerve growth factor (NGF) and other neurotrophic factors.^3,4 Because BDNF/TrkB signalling is central to how neurons adapt and form connections, this neurotrophin effect is the axis around which most of the Semax literature is organized.

Two 2006 papers by Dolotov and colleagues are the usual reference points. One, in Brain Research, reported that Semax regulates BDNF and TrkB expression in the rat hippocampus; the other, in the Journal of Neurochemistry, reported that the peptide binds specifically in the rat basal forebrain and increases BDNF protein there.^3,4 Beyond the neurotrophins, the literature describes several other threads. Semax has been reported to activate the brain’s serotonergic and dopaminergic systems in animal models, producing antidepressant-like and anxiolytic-like behaviour in those models. It has been characterized as interacting with the melanocortin receptors — specifically as competitively antagonizing the action of α-melanocyte-stimulating hormone at the MC4 and MC5 receptors, consistent with the ACTH lineage of its parent sequence. And like Selank, it has been shown to inhibit enkephalin-degrading enzymes in human serum in vitro, though the significance of that property is described in the literature as uncertain.

An honest account has to note the gap that runs underneath all of this. Despite the depth of the literature, the precise first molecular target of Semax — the single receptor it binds to initiate its cascade, if one such receptor exists — has never been fully pinned down; reviews of the peptide describe its mechanism as still not completely understood. It is a compound whose downstream fingerprint on the brain (the BDNF rise, the neurotransmitter shifts) is much better documented than its first point of contact. For readers placing this beside other compounds the catalogue carries, that makes Semax a useful contrast: where a growth-hormone secretagogue such as CJC-1295 has a clearly defined receptor, Semax is a peptide characterized mostly by what it changes rather than by where it first binds.

The research record

Semax sits in an unusual place: it is far more heavily studied than most research peptides, but almost all of that study happened inside one national research system. The preclinical base is genuine and peer-reviewed — the neurotrophin work above, plus a long series of investigations into oxidative-stress markers, gene-expression profiling in neuronal tissue, and the pharmacokinetics conferred by the Pro-Gly-Pro tail. On top of that preclinical base, Russian investigators ran human clinical studies, and it is on the strength of those that Semax became a registered medicine there. That is more clinical development than the great majority of research peptides ever accumulate.

The caveat that has to travel with that record is its concentration and its reach. Much of the clinical literature is Russian-language, was conducted within a single regulatory system, and has not been reproduced in the large, independent, multi-country trials that Western drug approval demands. A deep literature is not the same thing as a globally validated one, and the two should not be conflated. The table below summarizes what the record establishes and where its edges are.

Registered in Russia, reviewed in the US

Semax has one of the most lopsided regulatory profiles of any compound in this catalogue, and laying it out plainly is the clearest way to read the molecule honestly. In Russia, Semax is an approved prescription medicine — it appears on the Russian government’s List of Vital and Essential Drugs, and its national marketing authorization lists neurological and cognitive indications. That is a real regulatory status, but it exists inside one country’s system and does not transfer. In the United States and most of the world, Semax has never been approved as a drug, has not been evaluated by the FDA for safety or efficacy, and is not a marketed medicine. Those two facts sit side by side and are both true; neither cancels the other, and neither describes what research-grade Semax does for any person.

The compound also re-entered the US regulatory conversation very recently, which is part of why interest in it has risen. Peptides sold and used outside the approved-drug system have drawn growing FDA attention, and on July 23–24, 2026 the agency’s Pharmacy Compounding Advisory Committee met at the FDA’s White Oak campus to review a slate of seven peptides — Semax among them, alongside BPC-157, TB-500, KPV, MOTS-c, DSIP (listed as emideltide), and Epithalon — as candidates for the 503A bulk drug substances list that governs what licensed pharmacies may compound.⁵ The committee voted 8 in favour, 5 opposed, with 1 abstention to recommend Semax for inclusion.⁵ Two things about that vote need stating precisely, because it is easy to overread. First, a Pharmacy Compounding Advisory Committee recommendation is advisory only: the committee does not make law and does not issue approvals, and the FDA can accept, reject, or defer the recommendation. Second, the entire question in that room concerned the compounding-pharmacy pathway — whether pharmacists could prepare the substance for patients — which is a separate regulatory world from the sale of a compound as a research chemical.

None of that changes the footing on which a research supplier operates. Whatever a compound’s regulatory trajectory, and however a distant advisory committee votes, research-grade Semax is laboratory material, sold for in-vitro research use only, and the current attention on the category is a reason to be more precise about that framing, not less. The site’s guide to how peptides differ from drugs and biologics covers why these categories are drawn where they are, and why a research chemical, a compounded drug, and an approved medicine are three different things even when the molecule is the same.

Bench practice: characterizing a methionine peptide

Semax is supplied as a lyophilised (freeze-dried) solid, and the analytical questions a laboratory should be able to answer about a vial follow directly from the chemistry. Two properties define the target: the correct seven-residue sequence, and the intact, un-oxidized state of that sequence. A credible certificate of analysis should let a buyer confirm both.

Identity is established by mass spectrometry: the measured mass should match the expected value for the peptide, near 813.9 for the free base. Purity is established by reversed-phase HPLC, which separates the intended molecule from synthesis-related impurities such as deletion sequences and truncated chains. For Semax there is one impurity that deserves particular attention, and it comes from that N-terminal methionine: methionine is one of the most oxidation-prone amino acids, and its sulphur can pick up an oxygen to form methionine sulphoxide. A vial that has been exposed to air, heat, or light for too long can accumulate the oxidized form, which is a different molecule — heavier by sixteen mass units and separable by HPLC — even though the sequence on paper is unchanged. Disciplined analytics catch that; a label alone does not. Beyond identity and purity, a thorough COA reports net peptide content (how much of the vial’s mass is actually peptide rather than water and counter-ions), the counter-ion itself (commonly acetate or trifluoroacetate), and endotoxin levels where that matters.

Stability follows the general rules for the class, with that methionine caveat layered on top. As a dry, lyophilised solid kept cold and protected from light and moisture, the peptide is comparatively stable; once reconstituted it is far more vulnerable, and the oxidation-prone methionine makes protection from air and light more than a formality. The site’s storage guide and its account of how peptides degrade cover the practical handling; none of that is a use instruction, only the analytical hygiene that lets a laboratory trust that what is in the vial matches the label. Because Semax is a peptide, it also shares the class’s basic constraint on how it can be studied at all: short peptides are broken down in the digestive tract, which is why the research literature relies on parenteral routes rather than oral ones — a limitation the peptide-versus-drug explainer unpacks.

What the evidence does not establish

Semax attracts more claims than its evidence supports, and the corrective is to state the boundaries directly. The preclinical and mechanistic work — the BDNF and TrkB findings, the neurotransmitter effects, the melanocortin interactions — is real and peer-reviewed, but it describes what the peptide does in cells and in animal models and in studies conducted largely within one national research system. It does not amount to an independently validated, globally reproduced demonstration of any effect in people, and it says nothing about outcomes for any individual. The registered medical status in Russia is a fact about that country’s regulatory system, not a universal endorsement, and the July 2026 FDA advisory vote was a procedural recommendation about compounding eligibility, not a finding that Semax is safe or effective.

The popular framing of Semax as a ready-made “nootropic” is exactly the kind of shorthand a research audience should hold at arm’s length: it collapses a genuinely interesting but incomplete record — a deep preclinical literature, an unresolved primary mechanism, and a clinical history confined to one regulatory system — into a slogan the evidence has not earned. For placing the compound against its nearest research relatives, the Semax versus Selank comparison and the broader survey of cognition-related research peptides are the honest reference points.

The honest summary is that Semax is a thoroughly studied, chemically well-defined research peptide with an instructive mechanism and an unusual regulatory history — and that this combination is exactly what makes it a legitimate subject for laboratory investigation, and exactly why it belongs in a research setting and nowhere else.

Frequently asked questions

Is Semax the same thing as ACTH?

No. Semax is a short synthetic peptide, only seven amino acids long, built from a small piece of the much larger adrenocorticotropic hormone (ACTH) and then modified. Its first four residues correspond to the ACTH(4–7) fragment, which is the neurotrophic part of that region; the last three are an added Pro-Gly-Pro tail that the natural hormone does not have. The design deliberately keeps the neurotrophic character of that ACTH region while shedding the adrenal, steroid-producing (corticotropic) activity of the full hormone entirely. So Semax is best described as a stabilized analogue of a neurotropic ACTH fragment, not ACTH itself.

Is Semax approved by the FDA?

No. Semax has never been approved by the FDA as a drug for any indication, and it has not been evaluated or marketed as a medicine in most countries. It is a registered pharmaceutical only in Russia and a few neighbouring states. In July 2026 an FDA advisory committee reviewed Semax, alongside six other peptides, as a candidate for the 503A compounding bulks list and recommended it for inclusion by an 8–5–1 vote, but a committee recommendation is advisory only and is not an approval, an efficacy finding, or a statement that the peptide is safe or effective for anyone.

What is the difference between Semax and N-acetyl Semax?

They share the same seven-residue core but differ at the ends of the chain. N-acetyl Semax carries an acetyl group added to the N-terminus, and the further variant usually called N-acetyl Semax amidate also has the C-terminus converted to an amide. Both modifications are chemical changes made to slow enzymatic breakdown of the peptide, which is why the acetylated forms are frequently offered as separate research items. From an analytical standpoint they are distinct molecules with different masses, and a certificate of analysis should identify which one a vial actually contains.

How is Semax related to Selank?

They are siblings from the same research programme rather than the same molecule. Both were developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, and both use the same trick for stability: appending a Pro-Gly-Pro tail that resists the enzymes which would otherwise degrade a short peptide quickly. But their parent sequences are different. Semax derives from a fragment of ACTH and is studied mainly in neurotrophic contexts, while Selank derives from the immune peptide tuftsin and is studied mainly in anxiolytic and immunomodulatory ones. The site’s Semax versus Selank comparison walks through the distinction in detail.

Is Semax intended for human use?

No. Semax supplied by Patriot Labs is sold strictly for in-vitro research and laboratory use only. It is not for human or veterinary consumption, and nothing in this guide describes how to administer it. The registered medicine that exists in Russia is a separate, nationally regulated product; research-grade Semax is a laboratory material characterized for identity and purity, and that is the only footing on which it is offered here. For the practical side of sourcing verified material, see the guide on storing research peptides and the COA explainer.

References

All Patriot Labs products are sold strictly for in-vitro research and laboratory use only. Not for human or veterinary consumption. This guide is educational and describes peptide chemistry and published research in general terms; it is not medical advice, does not describe how to use any product, and the references cited do not constitute a product claim.